诸如Wegovy和Mounjaro等重量损失药物正在英国造成获取机会的差异,原因是严格的国民保健制度规则、高昂的成本和区域不平等。 Weight-loss drugs like Wegovy and Mounjaro are creating access disparities in the UK due to strict NHS rules, high costs, and regional inequalities.

Wegovy和Mounjaro等重量损失药物在抑制食欲和帮助大量减肥方面起到了有效作用,在联合王国造成了严重的准入差距。 Weight-loss drugs like Wegovy and Mounjaro, effective at suppressing appetite and aiding significant weight loss, are creating major access disparities in the UK. 虽然可在国民保健制度上查阅,但严格和不一致的资格标准(如高BMI阈值)和地区在开具处方方面的差异导致了 " 花旗彩票 " ,而获得彩票取决于地点。 Though available on the NHS, strict and inconsistent eligibility criteria—such as high BMI thresholds—and regional differences in prescribing have led to a "postcode lottery," where access depends on location. 90%以上的用户支付私人费用,每月支出100至350英镑,使许多人无法负担治疗费用,特别是在肥胖率较高的低收入地区。 Over 90% of users pay privately, spending £100 to £350 monthly, making treatment unaffordable for many, especially in lower-income areas where obesity rates are higher. 由于英格兰只有一小部分国民保健制度董事会开通了Mounjaro并担心价格可能会上涨,专家们警告说,这些改变生命的治疗有可能成为一种奢侈品,加深健康不平等,破坏公共卫生目标。 With only a fraction of NHS boards in England prescribing Mounjaro and concerns over potential price increases, experts warn these life-changing treatments risk becoming a luxury, deepening health inequalities and undermining public health goals.